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Hepatocellular carcinoma (HCC) is one of the solid cancers with 
a dismal prognosis, particularly when it is diagnosed in the unre-
sectable/advanced stage.1 Owing to the increasing incidence of 
HCC in developed countries over the last decade,2 there has been 
a remarkable progress in the development of novel drugs for sys-
temic treatment, enabling HCC to escape from being classified as 
an “orphan tumor.” Indeed, several tyrosine kinase inhibitors, in-
cluding sorafenib, lenvatinib, regorafenib, and cabozantinib, have 
been approved as first- or second-line systemic therapies for pa-
tients with unresectable HCC.3-6 Furthermore, nivolumab, which is 
a immune checkpoint inhibitor targeting programmed cell death 
protein 1 (PD-1) on cytotoxic T cells, and ramucirumab, a mono-
clonal antibody inhibiting vascular endothelial growth factor re-
ceptor 2 (VEGFR2), have been approved as second-line systemic 
therapies with an action mechanism different from that of tyro-
sine kinase inhibitors.7,8 With various systemic therapeutic options 
now available, liver specialists treating patients with HCC have to 
answer a new question: what is the optimal second-line systemic 
treatment option after sorafenib failure?
Regarding this issue, Lee et al.9 reported comparable efficacy 
and safety between nivolumab and regorafenib in patients with 
advanced disease (Barcelona Clinic Liver Center [BCLC] stage B or 
C) who had experienced sorafenib failure. Their retrospective 
study was conducted at a single institution, and most of the en-
rolled patients had BCLC stage C disease (96.7%). In 102 and 48 
patients who were treated with nivolumab and regorafenib, the 
median overall survival (OS) was 5.9 months and 6.9 months, re-
spectively (P=0.77). There was no significant difference in disease 
control rates between the nivolumab and regorafenib groups 
(50.0% vs. 47.1%; P=0.58), but the objective response rate with 
nivolumab was higher than that with regorafenib (16.7% vs. 
5.9%; P=0.041). There was no significant difference in time to 
progression (TTP) between the two groups (4.0 vs. 3.3 months; 
P=0.4). The median OS and TTP of regorafenib-treated patients in 
the study were lower compared to the RESORCE trial,5 possibly 
due to the larger proportion of patients with macrovascular inva-
sion and BCLC stage C in the current study. Some patients (5.9%) 
on regorafenib had prior sorafenib intolerance, which may have 
lowered OS or TTP compared to the outcomes reported in the 
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RESORCE trial, as longer duration of sorafenib treatment is associ-
ated with better OS and TTP with subsequent regorafenib treat-
ment.10 In contrast, the median OS of nivolumab-treated patients 
was consistent with that reported in a previous study.7 Indepen-
dent prognostic factors for OS were nivolumab treatment (hazard 
ratio [HR], 0.536; 95% confidence interval [CI], 0.300–0.957; 
P=0.04), male sex (HR, 2.587; 95% CI, 1.140–5.872; P=0.02), 
Child-Pugh class B (HR, 5.195; 95% CI, 2.073–13.018; P=0.001), 
and intrahepatic tumor burden (HR, 2.801; 95% CI, 1.019–7.703; 
P=0.046). Regarding safety, patients treated with nivolumab or 
regorafenib had comparable toxicity leading to premature drug 
discontinuation, mostly from hepatic decompensation. The au-
thors suggest that patients with Child-Pugh class B would tolerate 
nivolumab better than regorafenib, as there was no difference in 
discontinuation rates due to hepatic decompensation despite the 
larger number of patients with Child-Pugh class B in the nivolum-
ab group (18.8% vs. 3.9%; P=0.003).
The authors applied inverse probability of treatment weighting 
(IPTW) to reduce treatment selection bias, which is unavoidable 
in retrospective studies. In fact, the baseline characteristics were 
not well-balanced between the two groups. In addition to the dif-
ference in sample size (n=48 in nivolumab, n=102 in regorafenib), 
a greater proportion of patients in the nivolumab group (18.8%) 
had poor liver function (indicated by Child-Pugh score 7–9) com-
pared to those in the regorafenib group (3.9%). Additionally, the 
proportion of patients with intrahepatic tumor burden >50% 
tended to be higher in the nivolumab group (27.1%) than in the 
regorafenib group (18.6%), although the difference was not sta-
tistically significant (P=0.40). Even after IPTW, nivolumab treat-
ment remained a significant independent factor associated with 
prolonged OS (HR, 0.340; 95% CI, 0.177–0.653; P=0.001). How-
ever, in the multivariate analysis after IPTW, nivolumab treatment 
was not found to be an independent factor related to prolonged 
TTP (HR, 0.744; 95% CI, 0.394–1.405; P=0.36). Based on the re-
sults obtained using IPTW, the authors concluded that nivolumab 
treatment might be associated with prolonged OS compared to 
regorafenib treatment in patients who progressed afterwards or 
were intolerant of sorafenib.
Although IPTW estimation is now commonly used to control for 
confounding factors in nonexperimental studies of medical inter-
ventions,11 not all of the confounders could be adjusted. In the 
study by Lee et al.,9 the median duration of sorafenib treatment 
was 2.5 months (1.4–3.1) and 3.0 months (2.3–6.2) in the 
nivolumab and regorafenib groups, respectively (P<0.001). Con-
sidering that longer sorafenib treatment duration is associated 
with better response to regorafenib, and that physicians may pre-
fer regorafenib to nivolumab as the second-line treatment in case 
of a favorable response to sorafenib, there is a possibility that se-
lection bias which cannot be corrected by IPTW may persist. Liver 
function and tumor burden are the strongest prognostic factors, 
Figure 1. Proposed algorithm for the selection of systemic treatment after sorafenib failure. Potential options for sequential systemic therapies are 
presented. Regorafenib was the second-line therapy for patients who tolerated sorafenib (≥400 mg of sorafenib for 20 days or longer during the 
28-day period before PD) and progressed on sorafenib. Nivolumab or cabozantinib could be used for patients with intolerance to sorafenib. Ramuci-
rumab was reserved for second-line therapy in patients with (AFP concentration ≥400 ng/mL. Cabozantinib was the only drug listed as a third-line 
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particularly in advanced HCC patients who have experienced sys-
temic therapy. Ideally, it is desirable to conduct a randomized, 
controlled trial to compare the efficacy and safety between differ-
ent types of systemic therapies, but it is unlikely that global phar-
maceutical companies would proceed with such a trial, consider-
ing the high risk of a negative result. The alternative would be to 
collect nationwide large-scale data to mitigate biases such as the 
differences in sample size, tumor burden, liver function, and phy-
sicians’ preference between groups.
With the increasing availability of drugs for first- and second-
line systemic therapy for HCC, a critical question among physi-
cians will relate to treatment strategy. What would be the optimal 
sequence after failure of a first-line drug, such as sorafenib? How 
should new drugs and data be integrated into the evolving se-
quence paradigm? An important hurdle to overcome is the ab-
sence of useful biomarkers to guide physicians in selecting drugs 
for HCC, even though recently developed drugs have molecular or 
immunologic targets. Unfortunately, in a recent phase 3 clinical 
trial testing pembrolizumab, a monoclonal antibody targeting the 
PD-1 interaction with programmed death-ligand 1 (PD-L1), as sec-
ond-line therapy for HCC patients (KEYNOTE-240), the median OS 
was 13.9 months (95% CI, 11.6–16.0) for pembrolizumab versus 
10.6 months (95% CI, 8.3–13.5) for placebo (HR, 0.781; 95% CI, 
0.611–0.998; P=0.238).12 Consequently, if similar experience is 
possible with nivolumab, which has been accepted as a second-
line drug based on phase 1/2 data, the role of an immune check-
point inhibitor as rescue therapy after sorafenib failure might not 
be so promising.
At present, a possible approach to a systemic treatment strate-
gy can be suggested in light of the available data. Patients who 
were tolerant of sorafenib and had disease progression would be 
managed with regorafenib as second-line therapy, according to 
RESORCE trial.5 Cabozantinib, a multiple receptor tyrosine kinases 
inhibitor inhibiting VEGFR2, c-MET, and AXL, was approved as a 
second-line and third-line treatment for advanced HCC. In sub-
group analysis, cabozantinib demonstrated favorable effects in 
patients aged ≥65 years, males, and those with extrahepatic 
spread.6 Patients who discontinued sorafenib due to toxicity 
would be considered for nivolumab, cabozantinib, or ramucirum-
ab. Nivolumab was tested in an open-label, non-comparative, 
phase 1/2 dose study (Checkmate 040) that assessed the safety 
and efficacy of nivolumab in patients with HCC who failed 
sorafenib treatment or other systemic therapy and those who 
were intolerant to sorafenib.7 Ramucirumab, for which survival 
benefit compared to placebo is not meaningful in patients who 
failed or were intolerant to sorafenib (8.5 vs. 7.3 months), showed 
improved survival in patients whose alpha-fetoprotein (AFP) con-
centrations are 400 ng/mL or greater.8 Therefore, ramucirumab 
should be restricted to patients whose AFP concentrations are 
400 ng/mL or greater in both sorafenib intolerant and tolerant 
patients (Fig. 1).8 However, CELSTIAL trial (phase 3 double-blind 
placebo-controlled trial randomizing 773 HCC patients to cabo-
zantinib or placebo in the second- or third-line setting) also re-
ported favorable response to this particular subgroup (AFP >400 
ng/mL); therefore, uncertainty remains on the superiority of ramu-
cirumab over other treatment agents as second-line therapy fol-
lowing sorafenib failure.6 When choosing the type of systemic 
therapy, it is important to consider the cost-effectiveness. One 
study reported that cabozantinib would not be cost-effective as 
the second-line therapy in advanced HCC.13 In the near future, the 
systemic treatment paradigm will be changed as lenvatinib be-
comes increasingly used as a first-line therapy, and the combina-
tion of atezolizumab with bevacizumab has shown promising re-
sults as the first-line treatment in a recent phase 3 trial. With 
rearrangement of first-line systemic therapies in practice, the need 
to select the optimal second-line treatment will again be raised. It 
remains unclear whether individual tumor biology would help to 
establish predictive biomarkers in HCC and to allocate the most 
effective drug to the right patient. Until biomarker-driven therapy 
is realized, efforts should be focused on identifying the special 
sub-cohorts of patients who respond to individual systemic treat-
ments.
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